冠心舒通胶囊(GXST),由五种中药组成,在中国长期用于心血管疾病的治疗,如冠状动脉疾病和心肌梗塞。然而,GXST对心肌损伤(MI)的影响尚未详细研究。在这些实验中,我们发现GXST降低了MI相关的心室重构(VR),降低了舒张期室间隔厚度(IVSd),左心室后壁收缩期直径(LVPWs),和左心室后壁舒张期直径(LVPWd),以改善心功能和结构,通过超声心动图测量。此外,组织学分析表明,GXST可以改善心肌的病理改变。天狼星红染色,小麦胚芽凝集素染色和炎症相关的免疫组织化学结果表明GXST改善了纤维化区域,心脏肥大和炎症(IL-6和TNF-α)。此外,GXST上调细胞间连接蛋白(N-cad和Cx-43),下调血管生成相关蛋白(PDGF和VEGFA),心肌纤维化相关蛋白(TGF-β1),和基质金属蛋白酶(MMP-2和MMP-9)。我们还发现GXST中剂量组(1g/kg/d)剂量最有效。总之,GXST通过降低VR保护心脏组织免受MI,从而表明GXST在MI治疗中的潜在应用。
Guanxinshutong capsule (GXST), which consists of five traditional Chinese medicines, has been used for a long time in China for the treatment of cardiovascular diseases, such as coronary artery disease and myocardial infarction. However, the effects on GXST on myocardial injury (MI) have not been studied in detail. In these experiments, we found that GXST administration decreased MI-associated ventricular remodeling (VR) with a reduction in interventricular septal thickness in diastole (IVSd), left ventricular posterior wall diameter in systole (LVPWs), and left ventricular posterior wall diameter in diastole (LVPWd) to ameliorate cardiac function and architecture, as measured by echocardiography. Furthermore, histological analysis showed that GXST could ameliorate pathological alterations in the myocardium. And Sirius red staining, wheat germ agglutinin staining and inflammation-related immunohistochemistry results showed that GXST ameliorated the fibrosis areas, cardiac hypertrophy and inflammation (IL-6 and TNF-α). In addition, GXST upregulated intercellular junction proteins (N-cad and Cx-43) and downregulated the angiogenesis-related proteins (PDGF and VEGFA), myocardial fibrosis-related proteins (TGF-β1), and matrix metalloproteinase (MMP-2 and MMP-9). We also found that GXST medium-dose group (1 g/kg/d) dosage was the most efficacious. In conclusion, GXST protected cardiac tissues against MI by reducing VR, thus indicating the potential application of GXST in the treatment of MI.